Sign in

You're signed outSign in or to get full access.

PL

ProPhase Labs, Inc. (PRPH)·Q4 2024 Earnings Summary

Executive Summary

  • Q4 2024 EPS missed materially: actual $(1.59) vs Wall Street consensus $(0.24); revenue consensus was $3.77M, but the company did not disclose quarterly revenue separately in the 8-K/press release. Bold miss on EPS reflects restructuring costs and transition away from COVID testing to new initiatives [Q4 EPS/Revenue consensus from S&P Global]*.
  • Management pivoted the business: sold Pharmaloz for ~$23.6M in Jan-2025 to extinguish >$20M of debt and obligations, cut headcount from 96 to 28, and shut the Nebula lab to reduce overhead, positioning for improved margins in 2025 .
  • Commercialization path for BE‑Smart esophageal test: manuscript submission targeted in 4–8 weeks, cash‑pay launch while CPT coding pursued; partnering discussions with large cancer diagnostics continue .
  • Liquidity plan: Crown Medical initiative to recover unpaid COVID receivables with ~$50M net potential; management expects initial cash flows in H2 2025 and is exploring sale of Nebula/DNA Complete and a non‑dilutive loan/LOC to bridge operations .

What Went Well and What Went Wrong

  • What Went Well

    • Strategically refocused portfolio and balance sheet: pharmaloz sale (~$23.6M) removed >$20M debt, leases, and payables; HQ move targets ~$1M annual savings; Nebula lab shutdown saves ~$6M overhead .
    • BE‑Smart commercialization plan: cash‑pay diagnostic launch while CPT codes pursued; manuscript preparation with Mayo Clinic; proprietary 8 protein markers and low tissue requirements highlighted as differentiation .
    • Clear liquidity roadmap: Crown Medical collections (~$50M net potential) and exploration of selling Nebula/DNA Complete to unlock cash; management emphasized non‑dilutive financing .

  • What Went Wrong

    • EPS sharply worse in Q4: actual $(1.59) vs consensus $(0.24), reflecting restructuring, loss of COVID testing revenue, and elevated G&A tied to genomics/marketing initiatives [Q4 EPS consensus/actual from S&P Global]* .
    • Full‑year revenue fell 80.6% (to $6.8M) as COVID diagnostics went to zero; gross margin turned to a loss, driven by diagnostics collapse and transitional costs .
    • Cash remained tight exiting FY 2024 ($0.7M), necessitating near‑term bridge financing; Nasdaq minimum bid price risk acknowledged, with extension plan if needed .

Financial Results

Quarterly trend (actuals where disclosed; consensus shown for Q4)

MetricQ2 2024Q3 2024Q4 2024
Revenue ($USD Millions)$2.474 $3.146 — (company did not disclose Q4 revenue separately)
Diluted EPS ($)$(0.33) $(0.35) $(1.59)*
Gross Margin (%)(19.2)% (5.2)% —
EBITDA ($USD Millions)$(6.180) $(5.547) —

Q4 2024 consensus vs actual

MetricQ4 2024 ConsensusQ4 2024 Actual
Revenue ($USD Millions)$3.770*N/A (not disclosed)
Primary EPS ($)$(0.24)*$(1.59)*

Full-year comparison (context for trajectory)

MetricFY 2023FY 2024YoY Change
Net Revenue ($USD Millions)$35.0 $6.8 (80.6)%
Gross Profit (Loss) ($USD Millions)$15.6 $(0.2) n/m
G&A ($USD Millions)$33.4 $37.9 +$4.4
Net Loss ($USD Millions)$(16.8) $(53.4) n/m

Segment/structural context (FY)

ItemFY 2024 Detail
Diagnostics volumes~0 tests vs ~480k in FY 2023
Net revenue drivers−$24.8M diagnostics; −$3.4M consumer products
Cost of revenues (FY 2024)$2.3M diagnostics; $4.6M consumer products

KPIs and balance sheet snapshot (as of 12/31/2024)

KPIValue
Accounts Receivable, net ($USD Millions)$20.058
Cash & Equivalents ($USD Millions)$0.678
HeadcountReduced from 96 to 28
Pharmaloz sale (Jan-2025)~$23.6M; removed >$20M debt/obligations

Note: Asterisks denote values retrieved from S&P Global. Values retrieved from S&P Global.

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
BE‑Smart manuscript~Apr–Jun 2025In preparation (Q3’24) Submit in 4–8 weeks; decision 4–8 weeks post‑submission Clarified timeline
BE‑Smart commercialization2025LDT/FDA pathways; late‑2025 commercialization considered Cash‑pay launch while CPT pursued; leverage KOLs; no balance billing Strategy refined
BE‑Smart pricing/reimbursementInitial cash‑payTarget ~$2,500/test; acceptable economics even with ~⅓ reimbursement rate during trial phase Maintained; reinforced economicsMaintained
Crown Medical collectionsH2 2025$70M+ gross claims pursued (Q3’24) ~$50M net potential; initial inflows as soon as H2 2025 Quantified; timing framed
Nebula/DNA Complete2025Ramp DTC; strategic alternatives under evaluation Early‑stage sale exploration to unlock immediate cash Expanded to monetization
Operating structure2025−$6M overhead plan (Q3’24) Executed lab shutdown; HQ savings (~$1M/yr); post‑Pharmaloz overhead reductions Implemented

Earnings Call Themes & Trends

TopicQ2 2024 (Q‑2)Q3 2024 (Q‑1)Q4 2024 (Current)Trend
Balance sheet/overheadSeasonality and overhead reduction plan (−$6M) Strategic alternatives; DCF ramp; cost cuts Lab shutdown ($6M), HQ savings ($1M), Pharmaloz sale improves balance sheet Executing reductions
BE‑SmartFHC engaged; LDT/FDA path; large target market Partnership discussions with multi‑billion cancer firms Manuscript in 4–8 weeks; cash‑pay launch; CPT pursuit; protect spend From planning to pre‑launch
Liquidity/A/RGovernment/insurer A/R strategy forming A/R recovery discussed alongside Pharmaloz sale prospects Crown Medical ~$50M net; bankruptcy‑court tactic for efficiency; H2’25 inflows More concrete
DTC GenomicsNew marketing platform; DNA Complete/Expand launch Holiday ramp; subscriptions margin focus Lab shutdown; multi‑lab partnerships; subscription renewals drive profits Margin/scale focus
Macro/tariffsPotential tariff risk, onshoring benefits to PMI —PMI sold; de‑risked exposure Exposure reduced

Management Commentary

  • “We sold Pharmaloz Manufacturing for $23,000,000… retired most of the debt… cleaned up the balance sheet” .
  • “We have on our books right now approximately $20,000,000 in accounts receivable… Crown Medical… believe they are going to net us $50,000,000” .
  • “We’re going to roll [BE‑Smart] out and our goal is to get in GI’s offices this year… without breaking the bank” .
  • “I am not going to spend significant amounts of money… to commercialize this test… the goal is to partner… for a lot of money, but you have to go through the steps to prove it” .
  • “Shut down the laboratory… cut headcount dramatically… move our headquarters… save close to a million dollars a year” .

Q&A Highlights

  • CPT timeline and commercialization approach: Company will use generic CPT codes initially where possible; expects cash‑pay launch to build adoption and payer dialogue; reiterated disciplined spend .
  • Reverse split risk: Management expects to regain compliance without reverse split, citing potential liquidity events and Nasdaq’s typical 6‑month extension after initial window .
  • Burn rate and cost cuts: Lab shutdown estimated to cut ~$6M overhead; PMI lost >$2M in 2024; HQ move targets ~$1M annual savings; broader IT and staff reductions implemented .
  • Cash and financing: Cash was ~$0.7M at 12/31/24; management working on a multi‑million non‑dilutive loan/LOC to bridge until asset sale or A/R inflows .
  • BE‑Smart pricing/economics: Indicative cash‑pay pricing around $2,500/test; viable even with ~⅓ reimbursement during initial phase; focus is adoption and KOL engagement .

Estimates Context

  • Q4 2024 EPS missed consensus: actual $(1.59) vs $(0.24) consensus; revenue consensus $3.77M, but the company did not disclose Q4 revenue separately. Expect downward estimate revisions near‑term until new run‑rate stabilizes post‑restructuring [Q4 EPS/Revenue consensus/actual from S&P Global]*.
  • Prior quarters showed smaller losses (Q2 $(0.33), Q3 $(0.35)), highlighting step‑up in Q4 restructuring impact vs estimates .

Note: Asterisks denote values retrieved from S&P Global. Values retrieved from S&P Global.

Key Takeaways for Investors

  • Bold EPS miss and undisclosed quarterly revenue reinforce near‑term uncertainty; the stock’s narrative will hinge on execution of liquidity events (Crown Medical collections, potential Nebula sale) and BE‑Smart early commercialization milestones .
  • Structural simplification (Pharmaloz sale, lab shutdown, HQ move) materially improves forward cost base and reduces financing risk; watch Q2–Q3 2025 for operating leverage evidence .
  • BE‑Smart’s cash‑pay rollout plus manuscript publication are near‑term catalysts; a partnership with a large cancer diagnostics player could accelerate adoption and de‑risk funding needs .
  • Genomics DTC strategy emphasizes subscriptions and outsourced labs to improve margins; track DNA Complete/Expand marketing conversion and renewal rates under new COO .
  • Balance sheet/liquidity: monitor timing/magnitude of A/R recoveries and any non‑dilutive credit facilities to bridge to H2 2025; cash was $0.7M at year‑end .
  • Governance/Nasdaq compliance: management plans extension and sees multiple pathways to >$1 share price without reverse split contingent on liquidity events .
  • Trading implications: near‑term volatility likely until disclosure cadence normalizes; catalysts include BE‑Smart manuscript, initial cash‑pay deployments, Crown Medical settlements, and any asset sale updates .